Gene: MARK4

57787
MARK4L|MARK4S|MARKL1|MARKL1L|PAR-1D
microtubule affinity regulating kinase 4
protein-coding
19q13.32
Ensembl:ENSG00000007047 MIM:606495 Vega:OTTHUMG00000181769 UniprotKB:Q96L34
NC_000019.10
SNP Mapped
1   ANCO-SNPs
AD
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.996e-2 (AD)  9.112e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs344797chr19:45304884 (GRCh38.p7)T>Galcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
GSK3A0.958
DNAJC50.953
RUSC20.951
DMTN0.951
MAPRE30.949
AP2A10.949
SPRYD30.949
MAPK8IP30.948
PPP2R5B0.948
EEF1A20.946

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
OR4F5-0.67
OR4F29-0.623
TFPI2-0.421
RAI14-0.391
KCNJ15-0.383
REST-0.381
CLEC2B-0.373
IL18RAP-0.369
CST7-0.368
WWTR1-0.365

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0303702-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone"2-methoxy-5-(2',3',4'-trimethoxyphenyl)tropone results in decreased expression of MARK4 mRNA"20206263
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in decreased expression of MARK4 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MARK4 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MARK4 mRNA"27188386
D000082AcetaminophenAcetaminophen results in increased expression of MARK4 mRNA22230336
D000082AcetaminophenAcetaminophen affects the expression of MARK4 mRNA17562736
C016601afimoxifeneMARK4 results in decreased susceptibility to afimoxifene21233418
D001280AtrazineAtrazine results in decreased expression of MARK4 mRNA25929836
C006703benzo(b)fluoranthenebenzo(b)fluoranthene results in increased expression of MARK4 mRNA26377693
D001564Benzo(a)pyreneBenzo(a)pyrene results in increased expression of MARK4 mRNA21569818
C006780bisphenol Abisphenol A results in decreased expression of MARK4 mRNA25181051
C012843cinnamic aldehydecinnamic aldehyde results in decreased expression of MARK4 mRNA17178418
C000944dicrotophosdicrotophos results in increased expression of MARK4 mRNA28302478
D048628KetolidesKetolides analog results in increased expression of MARK4 mRNA24967691
D007854LeadLead affects the splicing of MARK4 mRNA28903495
C045463leflunomideleflunomide results in increased expression of MARK4 mRNA28988120
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in increased expression of MARK4 mRNA"25554681
D037742Nanotubes, Carbon"Nanotubes, Carbon results in increased expression of MARK4 mRNA"25554681
C507134ON 01910ON 01910 results in increased expression of MARK4 mRNA22351695
D010662Phenylmercuric Acetate"[NOG protein co-treated with Phenylmercuric Acetate co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MARK4 mRNA"27188386
D010662Phenylmercuric AcetatePhenylmercuric Acetate results in decreased expression of MARK4 mRNA26272509
D010936Plant ExtractsPlant Extracts results in decreased expression of MARK4 mRNA23557933
D018038Sodium SeleniteSodium Selenite results in increased expression of MARK4 mRNA18175754
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MARK4 mRNA22574217
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of MARK4 mRNA21570461
D013849ThimerosalThimerosal results in decreased expression of MARK4 mRNA27188386
D014520UrethaneUrethane results in increased expression of MARK4 mRNA28818685
D014635Valproic AcidValproic Acid affects the expression of MARK4 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of MARK4 mRNA22083351
C100058vanillinvanillin results in decreased expression of MARK4 mRNA17178418

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0004674protein serine/threonine kinase activity-IBA21873635  
GO:0004674protein serine/threonine kinase activity-IDA15009667  
GO:0004674protein serine/threonine kinase activity-NAS28386764  
GO:0005515protein binding-IPI14594945  14676191  16959763  23666762  
GO:0005524ATP binding-NAS15009667  
GO:0008017microtubule binding-IDA14594945  
GO:0043015gamma-tubulin binding-IDA14594945  
GO:0043130ubiquitin binding-NAS14594945  
GO:0050321tau-protein kinase activity-IBA21873635  
GO:0050321tau-protein kinase activity-IDA14594945  
GO:0050321tau-protein kinase activity-IMP23666762  27708431  
GO ID GO Term Qualifier Evidence PubMed
GO:0000226microtubule cytoskeleton organization-IBA21873635  
GO:0000226microtubule cytoskeleton organization-IMP14594945  
GO:0000226microtubule cytoskeleton organizationNOTIMP23400999  
GO:0001578microtubule bundle formation-IEP14594945  
GO:0006468protein phosphorylation-IMP23666762  
GO:0006468protein phosphorylation-TAS14594945  
GO:0007049cell cycle-IEA-  
GO:0007399nervous system development-IDA14594945  
GO:0035556intracellular signal transduction-IBA21873635  
GO:0043068positive regulation of programmed cell death-NAS15009667  
GO:0044782cilium organization-IGI23400999  
GO:0045724positive regulation of cilium assembly-IMP23400999  
GO:0046605regulation of centrosome cycle-IMP25123532  
GO:0051301cell division-IEA-  
GO:0097711ciliary basal body-plasma membrane docking-TAS-  
GO:1904781positive regulation of protein localization to centrosome-IMP23400999  
GO ID GO Term Qualifier Evidence PubMed
GO:0000930gamma-tubulin complex-IDA25123532  
GO:0005737cytoplasm-IBA21873635  
GO:0005737cytoplasm-IDA23666762  
GO:0005813centrosome-IDA14594945  25123532  
GO:0005815microtubule organizing center-IDA14594945  
GO:0005829cytosol-TAS-  
GO:0015630microtubule cytoskeleton-IDA14594945  
GO:0030425dendrite-IDA23666762  
GO:0030496midbody-IDA25123532  
GO:0036064ciliary basal body-IMP23400999  
GO:0043005neuron projection-IDA14594945  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-1852241Organelle biogenesis and maintenanceTAS
R-HSA-5617833Cilium AssemblyTAS
R-HSA-5620912Anchoring of the basal body to the plasma membraneTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal